Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Depreciation and Depletion (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Depreciation and Depletion for 3 consecutive years, with $600000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation and Depletion changed 0.0% to $600000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $2.5 million for FY2025, 4.17% up from the prior year.
  • Depreciation and Depletion for Q4 2025 was $600000.0 at Artiva Biotherapeutics, roughly flat from $600000.0 in the prior quarter.
  • The five-year high for Depreciation and Depletion was $600000.0 in Q3 2023, with the low at $500000.0 in Q2 2023.
  • Average Depreciation and Depletion over 3 years is $590909.1, with a median of $600000.0 recorded in 2023.
  • Peak annual rise in Depreciation and Depletion hit 20.0% in 2024, while the deepest fall reached 0.0% in 2024.
  • Over 3 years, Depreciation and Depletion stood at $600000.0 in 2023, then changed by 0.0% to $600000.0 in 2024, then changed by 0.0% to $600000.0 in 2025.
  • According to Business Quant data, Depreciation and Depletion over the past three periods came in at $600000.0, $600000.0, and $600000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.